Know Cancer

forgot password

A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer

Phase 1
Not Enrolling
Cervical Cancer

Thank you

Trial Information

A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer

Examines the effects of Topotecan and Cisplatin with radiation for advanced cervical cancer

Inclusion Criteria:

- Patients with histologically confirmed advanced cervical carcinoma who, following
optional surgical staging, are not deemed to be curable by either surgery or
radiotherapy alone. This includes patients with stages IIB, IIIA, IIIB or IVA and
stages IB or IIA who in addition have one of the following risk factors:

- Primary tumor > 6 cm

- Positive pelvic and/or para-aortic lymph nodes (resected or unresected)

- Positive surgical margins

- Depth of invasion greater than 50 % and positive capillary-lymphatic space

- Eligible cell types include squamous, adenosquamous and adenocarcinoma of the

- Patients may have measurable disease (defined as lesions which can be measured in at
least two (2) dimensions by physical examination or any medical imaging technique).
Inability to measure disease will not constitute exclusion criteria.

- Patients with GOG performance status of 0, 1, or 2.

- Patients will have recovered from the effects of recent surgery and should be free of
clinically significant infection.

- Patients must have adequate:

- Bone marrow function: WBC greater than or equal to 3,000 cells/mm3, platelet
count greater than or equal to 100,000 cells/mm3, and granulocyte count greater
than or equal to 1,500 cells/mm3.

- Renal function: Creatinine less than or equal to 2.0 mg/dl.

- Hepatic function: Bilirubin less than or equal to 1.5 x institutional normal,
SGOT and alkaline phosphatase less than or equal to 3 x institutional normal.

- Patients must have signed an approved informed consent.

- Patients have met the pre-entry requirements specified in Section 7.0

Exclusion Criteria:

- Patients with GOG performance of 3 or 4.

- Patients with another malignancy, prior or concomitant, other than skin (excluding

- Patients with septicemia, severe infection, gastrointestinal bleeding, or intestinal

- Patients with anatomic abnormalities requiring modification of radiation fields
(pelvic kidney, renal transplant, etc.).

- Patient with recurrent cervical cancer

- Patients who have received prior pelvic radiation

- Pregnant women and women of childbearing potential not using an effective form of

- History of thrombus (10/28/02)

- History of unstable angina or MI within the past six months. Patients with evidence
of abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible
if their disease has been stable for the past six months. (10/28/02)

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

disease progression

Outcome Time Frame:

disease progress or complete remission

Safety Issue:


Principal Investigator

Harriet Smith, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of New Mexico


United States: Institutional Review Board

Study ID:




Start Date:

March 2002

Completion Date:

December 2005

Related Keywords:

  • Cervical Cancer
  • Cancer
  • Cervix
  • Uterine Cervical Neoplasms



University of New MexicoAlbuquerque, New Mexico  87131